Sergio Cifuentes Canaval, Medical Oncologist at Las Américas Auna Clinic, shared a post on LinkedIn:
“Today I had the privilege of listening to Dr. Camilo Jiménez speak about the evolving landscape of metastatic paraganglioma and the transformative impact of belzutifan as a first-line therapy.
Dr. Jiménez is not only a global reference in endocrine oncology, but also the principal investigator of the phase III LITESPARK-015 clinical trial, recently published in the NEJM Group. This pivotal study represents a major step forward for patients with these rare tumors and exemplifies the power of rigorous, collaborative clinical research.
It is inspiring to see a Latin American physician leading such high-impact science. A reminder of what our region can contribute to the future of oncology.”
More posts featuring Sergio Cifuentes Canaval.